Código 293329 (Harmonized System 2012 by 6 digits)
2023: US$37.2M, Total Trade Exchange
2023: US$4.68M, International Sales
2023: US$32.5M, International Purchases
In 2023, the trade exchange (includes international purchases and sales) of Heterocyclic Compounds with Nitrogen Hetero [S] only with Imidazole Cycle, even Hydrogenated, in Structure (No Hydantoin and its Derivatives, and Products of Subheading 3002 10) was US$37.2M.
In 2023, the states with the most international sales in Heterocyclic Compounds with Nitrogen Hetero [S] only with Imidazole Cycle, even Hydrogenated, in Structure (No Hydantoin and its Derivatives, and Products of Subheading 3002 10) were Estado de México (US$4.67M) and Ciudad de México (US$3.82k).
The states with the most international purchases in 2023 were Jalisco (US$14.8M), Estado de México (US$9.59M), Ciudad de México (US$6.31M), Nuevo León (US$945k), and Querétaro (US$488k).
In 2023, the main commercial destinations of Heterocyclic Compounds with Nitrogen Hetero [S] only with Imidazole Cycle, even Hydrogenated, in Structure (No Hydantoin and its Derivatives, and Products of Subheading 3002 10) were India (US$3.34M), United States (US$819k), Australia (US$300k), South Korea (US$126k), and Turkey (US$30.2k).
The main commercial origins of Heterocyclic Compounds with Nitrogen Hetero [S] only with Imidazole Cycle, even Hydrogenated, in Structure (No Hydantoin and its Derivatives, and Products of Subheading 3002 10) in 2023 were China (US$15.9M), India (US$6.8M), Italy (US$2.89M), France (US$1.6M), and Czech Republic (US$1.23M).
In the global context, the main exporting countries of Heterocyclic Compounds with Nitrogen Hetero [S] only with Imidazole Cycle, even Hydrogenated, in Structure (No Hydantoin and its Derivatives, and Products of Subheading 3002 10) in 2022 were China (US$585M), France (US$404M), and India (US$318M). In the same year, the main importing countries of Heterocyclic Compounds with Nitrogen Hetero [S] only with Imidazole Cycle, even Hydrogenated, in Structure (No Hydantoin and its Derivatives, and Products of Subheading 3002 10) were United Kingdom (US$280M), United States (US$156M), and Japan (US$140M).
US$37.2M, Total Trade Exchange (2023)
In 2023, the total trade exchange of Heterocyclic Compounds with Nitrogen Hetero [S] only with Imidazole Cycle, even Hydrogenated, in Structure (No Hydantoin and its Derivatives, and Products of Subheading 3002 10) in Mexico (including international purchases and sales) was US$37.2M.
The visualizations show the net balance of Heterocyclic Compounds with Nitrogen Hetero [S] only with Imidazole Cycle, even Hydrogenated, in Structure (No Hydantoin and its Derivatives, and Products of Subheading 3002 10) at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
July, 2024
In July 2024, international sales of Heterocyclic Compounds with Nitrogen Hetero [S] only with Imidazole Cycle, even Hydrogenated, in Structure (No Hydantoin and its Derivatives, and Products of Subheading 3002 10) were US$801k, while international purchases reached US$3.07M. The above results in a trade balance of -US$2.27M.
2024-Q3: US$800k, International Sales
The visualization shows the quarterly concentration of international sales of Heterocyclic Compounds with Nitrogen Hetero [S] only with Imidazole Cycle, even Hydrogenated, in Structure (No Hydantoin and its Derivatives, and Products of Subheading 3002 10) at state level.
In the third quarter of 2024, international sales were US$800k, being the states with the most sales Estado de México (US$800k).
Estado de México: US$4.67M, State with the Most International Sales (2023)
India: US$3.34M, Main commercial destination (2023)
In 2023, the states with the highest international sales in Heterocyclic Compounds with Nitrogen Hetero [S] only with Imidazole Cycle, even Hydrogenated, in Structure (No Hydantoin and its Derivatives, and Products of Subheading 3002 10) were Estado de México (US$4.67M) and Ciudad de México (US$3.82k).
In 2023, the countries with the most international purchases from Mexico were India (US$3.34M), United States (US$819k), Australia (US$300k), South Korea (US$126k), and Turkey (US$30.2k).
Jalisco: US$14.8M, State with the Most International Purchases (2023)
China: US$15.9M, Main Commercial Origin (2023)
In 2023, the states with the highest international in Heterocyclic Compounds with Nitrogen Hetero [S] only with Imidazole Cycle, even Hydrogenated, in Structure (No Hydantoin and its Derivatives, and Products of Subheading 3002 10) were Jalisco (US$14.8M), Estado de México (US$9.59M), Ciudad de México (US$6.31M), Nuevo León (US$945k), and Querétaro (US$488k).
The countries with the most international sales to Mexico in 2023 were China (US$15.9M), India (US$6.8M), Italy (US$2.89M), France (US$1.6M), and Czech Republic (US$1.23M).
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Heterocyclic Compounds with Nitrogen Hetero [S] only with Imidazole Cycle, even Hydrogenated, in Structure (No Hydantoin and its Derivatives, and Products of Subheading 3002 10) and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Heterocyclic Compounds with Nitrogen Hetero [S] only with Imidazole Cycle, even Hydrogenated, in Structure (No Hydantoin and its Derivatives, and Products of Subheading 3002 10). On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
The visualizations show the global market for Heterocyclic Compounds with Nitrogen Hetero [S] only with Imidazole Cycle, even Hydrogenated, in Structure (No Hydantoin and its Derivatives, and Products of Subheading 3002 10). In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Heterocyclic Compounds with Nitrogen Hetero [S] only with Imidazole Cycle, even Hydrogenated, in Structure (No Hydantoin and its Derivatives, and Products of Subheading 3002 10) were China (US$585M), France (US$404M), and India (US$318M). In the same year, the main importing countries for Heterocyclic Compounds with Nitrogen Hetero [S] only with Imidazole Cycle, even Hydrogenated, in Structure (No Hydantoin and its Derivatives, and Products of Subheading 3002 10) were United Kingdom (US$280M), United States (US$156M), and Japan (US$140M).